Dean Y. Li is Director at RECURSION PHARMACEUTICALS, INC. (RXRX). They have made 5 open-market trades across 2 companies since 2021, most recently 2026-10-01.
CIK 0001837016
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MRK | 94,431 | $13.8M |
| RXRX | 1,476,707 | $5.1M |
| Total | $18.9M |
Shares reported on the most recent Form 4, priced at the 2026-10-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MRK | SELL | 2026-02-10 | 2026-02-10 | $117.52 | $1.2M | +5.8% | -1.0% | -4.9% |
| MRK | SELL | 2026-02-04 | 2026-02-06 | $118.77 | $1.8M | +0.4% | -3.5% | -7.5% |
| MRK | SELL | 2024-02-09 | 2024-02-12 | $125.50 | $1.8M | +2.8% | -3.0% | +2.6% |
| RXRX | SELL · 10b5-1 | 2024-01-09 | 2024-01-11 | $13.66 | $779K | -9.4% | -4.4% | -25.0% |
| RXRX | SELL | 2021-12-07 | 2021-12-09 | $20.48 | $326K | +0.3% | -18.1% | -59.2% |
| RXRX | SELL | 2021-11-17 | 2021-12-09 | $20.15 | $770K | +0.3% | -18.1% | -59.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.